Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · The Lancet Diabetes & Endocrinology · 36 citations
https://doi.org/10.1016/s2213-8587(23)00253-x
J
J Melville
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
8
Papers
88
Citations
5
h-index
2
i10-index
J Melville is an academic researcher. The author has contributed to research in topics: Sepsis Diagnosis and Treatment & COVID-19 Clinical Research Studies & Nosocomial Infections in ICU. The author has an h-index of 5, co-authored 7 publications.
Papers by this author
worksImmunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · The Lancet Child & Adolescent Health · 33 citations
https://doi.org/10.1016/s2352-4642(23)00316-4
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · The Lancet Infectious Diseases · 5 citations
https://doi.org/10.1016/s1473-3099(25)00093-3
Use of intravenous immunoglobulin to treat sepsis in a general ICU
2015 · Critical Care · 0 citations
https://doi.org/10.1186/cc14204
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · The Lancet Infectious Diseases · 0 citations
https://doi.org/10.1016/s1473-3099(25)00361-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat